MORGAN STANLEY PLC/PUT/NOVARTIS N/80/0.1/19.12.25 Share Price

Warrant

DE000MG2F3B1

Real-time Bid/Ask 13:37:22 10/06/2024 BST
0.34 EUR / 0.35 EUR +11.29% Intraday chart for MORGAN STANLEY PLC/PUT/NOVARTIS N/80/0.1/19.12.25
Current month-11.43%
1 month-27.91%
Date Price Change
10/06/24 0.34 +9.68%
07/06/24 0.31 -6.06%
06/06/24 0.33 +3.13%
05/06/24 0.32 -8.57%
04/06/24 0.35 -2.78%

Delayed Quote Börse Stuttgart

Last update June 10, 2024 at 12:04 pm

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellPUT
Underlying NOVARTIS AG
Issuer Morgan Stanley
WKN MG2F3B
ISINDE000MG2F3B1
Date issued 16/04/2024
Strike 80 CHF
Maturity 19/12/2025 (557 Days)
Parity 10 : 1
Emission price 0.66
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 0.64
Lowest since issue 0.31
Spread 0.01
Spread %2.86%

Company Profile

Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales (excluding discontinued operations) break down by therapeutic area as follows: - oncology (29.9%); - immunology (17.2%); - cardiovascular, renal and metabolic diseases (14.1%); - neuroscience (8.9%). The remaining net sales (29.9%) are from contract manufacturing of pharmaceutical products. At the end of 2023, Novartis AG had 33 production sites worldwide. Net sales are distributed geographically as follows: Europe (33%), the United States (39.5%), Asia/Africa/Australasia (20.5%), Canada and Latin America (7%).
Sector
-
More about the company

Ratings for Novartis AG

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Consensus: Novartis AG

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
105.9 USD
Average target price
110.2 USD
Spread / Average Target
+4.00%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW